Menu
Recruiting NCT06727370

Cognitive Screening in Lung Cancer Patients

— Observational Lung Disease NSCLC (Non-small Cell Lung Cancer) SCLC

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Lung Disease, NSCLC (Non-small Cell Lung Cancer), SCLC. Basic parameters: 18 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Italy
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

This study aims to investigate the occurrence of cancer and adjuvant therapy-related cognitive impairment in patients with both NSCLC and SCLC. The primary endpoint measure will be the presence of cognitive impairment during the first year after enrollment through the administration of a comprehensive neuropsychological assessment.

Primary outcome measures

  • cognitive impairment [Time frame: From baseline to 12 months]
Secondary outcome measures (1)
  • Risk factors on the cognitive profile of lung cancer patients [Time frame: From baseline to 12 months]

Eligibility criteria

Inclusion criteria

  • Small-cell and non-small-cell lung cancer (stage I, II, III, IV)
  • Age ≥ 18 years
  • Patients able to speak and read the local language(s) fluently
  • Acceptance and signature of informed consent

Exclusion criteria

  • Age ≥ 70
  • Presence of brain metastases
  • Patients with concomitant neurological or psychiatric disorders.
  • Patients undergoing brain radiotherapy
  • Previous diagnosis of lung cancer

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Case-control

Study locations

Italy · 1 center
  • Istituto Europeo di Oncologia — Milan

Identifiers

NCT: NCT06727370 · IEO 2027

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗